Cancer Medicine (Mar 2021)

A randomized, double‐blind, phase II study of oral histone deacetylase inhibitor resminostat plus S‐1 versus placebo plus S‐1 in biliary tract cancers previously treated with gemcitabine plus platinum‐based chemotherapy

  • Makoto Ueno,
  • Chigusa Morizane,
  • Masayuki Furukawa,
  • Daisuke Sakai,
  • Yoshito Komatsu,
  • Yousuke Nakai,
  • Masahiro Tsuda,
  • Masato Ozaka,
  • Nobumasa Mizuno,
  • Manabu Muto,
  • Akira Fukutomi,
  • Masafumi Ikeda,
  • Akihito Tsuji,
  • Akio Katanuma,
  • Toshikazu Moriwaki,
  • Takeshi Kajiwara,
  • Hiroshi Ishii,
  • Yuji Negoro,
  • Satoshi Shimizu,
  • Noriko Nemoto,
  • Shingo Kobayashi,
  • Keigo Makino,
  • Junji Furuse

DOI
https://doi.org/10.1002/cam4.3813
Journal volume & issue
Vol. 10, no. 6
pp. 2088 – 2099

Abstract

Read online

Abstract Purpose Effective second‐line chemotherapy options are limited in treating advanced biliary tract cancers (BTCs). Resminostat is an oral histone deacetylase inhibitor. Such inhibitors increase sensitivity to fluorouracil, the active form of S‐1. In the phase I study, addition of resminostat to S‐1 was suggested to have promising efficacy for pre‐treated BTCs. This study investigated the efficacy and safety of resminostat plus S‐1 in second‐line therapy for BTCs. Methods Patients were randomly assigned to receive resminostat or placebo (200 mg orally per day; days 1–5 and 8–12) and S‐1 group (80–120 mg orally per day by body surface area; days 1–14) over a 21‐day cycle. The primary endpoint was progression‐free survival (PFS). Secondary endpoints comprised overall survival (OS), response rate (RR), disease control rate (DCR), and safety. Results Among 101 patients enrolled, 50 received resminostat+S‐1 and 51 received placebo+S‐1. Median PFS was 2.9 months for resminostat+S‐1 vs. 3.0 months for placebo+S‐1 (HR: 1.154, 95% CI: 0.759–1.757, p = 0.502); median OS was 7.8 months vs. 7.5 months, respectively (HR: 1.049, 95% CI: 0.653–1.684, p = 0.834); the RR and DCR were 6.0% vs. 9.8% and 70.0% vs. 78.4%, respectively. Treatment‐related adverse events (TrAEs) of grade ≥ 3 occurring more frequently (≥10% difference) in the resminostat+S‐1 than in the placebo+S‐1 comprised platelet count decreased (18.0% vs. 2.0%) and decreased appetite (16.0% vs. 2.0%). Conclusions Resminostat plus S‐1 therapy improved neither PFS nor OS for patients with pre‐treated BTCs. Addition of resminostat to S‐1 was associated with higher incidence of TrAEs, but these were manageable (JapicCTI‐183883).

Keywords